Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

RALEIGH, N.C., Feb. 08, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to IV contract research organization, today announced the appointment of Eric Paul Pâques, previously the Chief Executive Officer for GRÜNENTHAL GROUP, to the Company’s Board of Directors.  Mr. Pâques joins the INC Research Board as an independent director and will be a Class I director serving a term ending at the Company’s 2018 Annual Meeting.

“We are pleased to welcome Eric to the INC Research Board,” said David Norton, Chairman of the Board of Directors. “Eric has spent his entire career in pharmaceuticals, and we believe his insight into this ever-changing industry will be invaluable to INC as we continue to expand worldwide and focus on being the ‘CRO of Choice’ for customers, employees and other stakeholders alike.  Eric brings to the board global experience in pharmaceutical management with specific expertise in both the sciences and finance.  We are delighted to have such a multi-faceted business professional join our Board to help guide the overall direction of our Company.”

Mr. Pâques started his career at Hoechst AG (later HMR and Aventis) before joining GRÜNENTHAL GROUP, a research-based family owned pharmaceutical company, in 1994.  During his career, he has held leadership positions in various areas of the organization, including Research & Development, M&A, and Licensing among others as well as Corporate Head of commercial organizations in several countries.   Mr. Pâques is currently a professor at the faculty for mathematics, informatics, and natural sciences at RWTH-AACHEN University in Germany. 

Mr. Pâques completed his undergraduate studies in chemistry, followed by his doctoral thesis at the Max-Planck-Institute of Biochemistry in Munich, Germany and the Université Catholique de Louvain in Belgium.  Mr. Pâques is Chairman of the Supervisory Board of Proteros Biostructure GmbH in Munich.

About INC Research
INC Research (Nasdaq:INCR) is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries.  Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market.  The Company was ranked “Top CRO to Work With” among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey.  INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 110 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research.

CONTACT: CONTACT: 
Investor Relations Contact:
Ronnie Speight
Vice President, Investor Relations
Phone: +1 (919) 745-2745
Email: [email protected]

Press/Media Contact:
Lori Dorer
Senior Director, Corporate Communications
Phone: +1 (919) 745-2890
Email: [email protected]

INC Research, LLC Logo

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).